Azithromycin and Ondansetron Safety With Respect to QT Prolongation
Concomitant azithromycin and ondansetron can increase the risk of QT interval prolongation because both agents have QT-prolonging/torsades de pointes warnings. [1,2,3] Even without known QT-prolongation risk, avoidance of additional risk factors and assessment for electrolyte/cardiac contributors is recommended because ECG monitoring is recommended when risk factors or other QT-prolonging drugs are present. [3,4]
QT Prolongation Risk Considerations
Azithromycin has been associated with serious heart rhythm changes, including QT prolongation and torsades de pointes. [1,2] Ondansetron has QT interval prolongation and torsades de pointes warnings, and ECG monitoring is recommended in higher-risk situations such as electrolyte abnormalities and bradyarrhythmias. [3,4]
Medication Selection Algorithm
Azithromycin (for bacterial indications) should be used only when clearly indicated and not for non-bacterial illness. [2] Ondansetron (for nausea/vomiting indications) should be avoided in congenital long QT syndrome. [3] When both drugs are needed, risk mitigation should focus on removing modifiable contributors to QT prolongation before dosing. [3,4]
Common Risk Factors That Increase Concern
Electrolyte abnormalities (hypokalemia and hypomagnesemia) increase ondansetron-associated QT risk and warrant ECG monitoring when present. [3,4] Congestive heart failure and bradyarrhythmias increase ondansetron-associated QT risk and warrant ECG monitoring when present. [3,4] Concomitant use of other medicinal products that prolong QT increases ondansetron-associated QT risk and warrants ECG monitoring when present. [3,4]
Initiation Thresholds and Monitoring Practices
ECG monitoring is recommended with ondansetron when there are electrolyte abnormalities (e.g., hypokalemia or hypomagnesemia), congestive heart failure, bradyarrhythmias, or use of other QT-prolonging drugs. [3,4] Avoidance is recommended for ondansetron in congenital long QT syndrome. [3]
Common Pitfalls to Avoid
Administration in the presence of hypokalemia or hypomagnesemia without correction and without ECG monitoring increases QT-associated risk. [3,4] Administration in patients with congenital long QT syndrome should be avoided. [3]
Targets and Goals of Therapy
The goal is prevention of medication-associated QT prolongation by addressing modifiable risks and using ECG monitoring when indicated by clinical risk features. [3,4] The goal is maintaining safe antiemetic treatment while minimizing additive QT-prolonging exposure from concurrent azithromycin and ondansetron. [1,3]
Clinical Bottom-Line Safety Statement
In an adult without known QT-prolongation risk factors, short-term coadministration can still pose an additive QT prolongation risk because both agents carry QT/torsades warnings. [1,2,3] If electrolyte abnormalities, heart failure, bradyarrhythmias, congenital long QT syndrome, or additional QT-prolonging drugs are present, ECG monitoring is recommended and ondansetron should be avoided in congenital long QT syndrome. [3,4]